

Inter Pharma Public Company Limited and its subsidiaries
Review report and interim financial information
For the three-month period ended
31 March 2024

Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Inter Pharma Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Inter Pharma Public Company Limited and its subsidiaries as at 31 March 2024, the related consolidated statements of comprehensive income, changes in shareholders' equity and cash flows for the three-month period then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Inter Pharma Public Company Limited for the same period (collectively "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Accounting Standard 34 Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of Review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 Interim Financial Reporting.

Siriwan Nitdamrong

Certified Public Accountant (Thailand) No. 5906

EY Office Limited

Bangkok: 13 May 2024

Inter Pharma Public Company Limited and its subsidiaries

Statements of financial position

As at 31 March 2024

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		31 March 2024 (Unaudited but reviewed)	31 December 2023 (Audited)	31 March 2024 (Unaudited but reviewed)	31 December 2023 (Audited)
Assets					
Current assets					
Cash and cash equivalents		383,313	412,390	232,662	252,170
Trade and other receivables	3	427,929	425,060	277,615	253,476
Advanced payments for purchase of goods		5,466	6,554	5,466	6,554
Inventories	4	342,459	345,270	99,712	100,347
Other current financial assets		854	855	326	323
Other current assets		9,699	12,720	3,546	3,650
Total current assets		1,169,720	1,202,849	619,327	616,520
Non-current assets					
Restricted bank deposits	10	61,547	61,547	50,800	50,800
Long-term loans to subsidiaries	2	-	-	112,200	141,200
Other non-current financial assets		36,289	36,289	36,289	36,289
Advance payment for business study	5	11,029	-	11,029	-
Investment in subsidiaries	6	-	-	1,102,230	1,102,230
Investment in joint venture	7	6,854	7,079	10,200	10,200
Investment properties		545	815	-	-
Property, plant and equipment	8	841,951	822,375	222,828	211,616
Right-of-use assets	9	104,971	106,897	2,715	2,884
Goodwill		477,851	477,851	-	-
Intangible assets		209,268	197,363	64,883	58,275
Deferred tax assets		16,758	15,910	5,900	5,373
Deposits		23,274	21,219	2,092	2,092
Other non-current assets		1,756	2,172	1,655	1,768
Total non-current assets		1,792,093	1,749,517	1,622,821	1,622,727
Total assets		2,961,813	2,952,366	2,242,148	2,239,247

The accompanying notes are an integral part of the financial statements.

Inter Pharma Public Company Limited and its subsidiaries

Statements of financial position (continued)

As at 31 March 2024

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		31 March	31 December	31 March	31 December
		2024	2023	2024	2023
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity					
Current liabilities					
Short-term loans from banks	10	40,000	40,000	-	-
Trade and other payables	11	323,935	321,510	70,929	64,347
Short-term loans from other person		6,100	6,100	-	-
Current portion of long-term loans from banks	12	53,360	54,427	46,060	46,052
Current portion of lease liabilities	13	35,703	38,892	619	610
Income tax payable		8,723	4,115	2,852	867
Current portion of provision for long-term employee benefits		2,351	2,787	983	1,182
Other current liabilities		10,589	10,915	8,293	8,332
Total current liabilities		480,761	478,746	129,736	121,390
Non-current liabilities					
Long-term loans from banks - net of current portion	12	187,466	200,657	173,274	184,792
Long-term loans from related parties	2	4,800	4,800	-	-
Lease liabilities - net of current portion	13	57,553	54,831	2,191	2,349
Provision for long-term employee benefits		34,348	32,748	15,092	15,054
Deferred tax liabilities		59,562	59,206	-	-
Provision for decommissioning costs		3,337	3,194	-	-
Other non-current liabilities		1,135	463	-	-
Total non-current liabilities		348,201	355,899	190,557	202,195
Total liabilities		828,962	834,645	320,293	323,585

The accompanying notes are an integral part of the financial statements.

Inter Pharma Public Company Limited and its subsidiaries

Statements of financial position (continued)

As at 31 March 2024

(Unit: Thousand Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	31 March 2024	31 December 2023	31 March 2024	31 December 2023
	(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
Liabilities and shareholders' equity (continued)				
Shareholders' equity				
Share capital				
Registered				
486,727,423 ordinary shares of Baht 0.50 each	<u>243,364</u>	<u>243,364</u>	<u>243,364</u>	<u>243,364</u>
Issued and fully paid up				
372,520,524 ordinary shares of Baht 0.50 each	186,260	186,260	186,260	186,260
Ordinary share premium	1,479,698	1,479,698	1,479,698	1,479,698
Surplus on share-based payment transactions	18,273	18,273	18,273	18,273
Surplus from business combination under common control	3,703	3,703	-	-
Retained earnings				
Appropriated - statutory reserve	23,153	23,153	23,153	23,153
Unappropriated	<u>217,896</u>	<u>202,100</u>	<u>214,471</u>	<u>208,278</u>
Equity attributable to owners of the Company	1,928,983	1,913,187	1,921,855	1,915,662
Non-controlling interests of the subsidiaries	<u>203,868</u>	<u>204,534</u>	-	-
Total shareholders' equity	<u>2,132,851</u>	<u>2,117,721</u>	<u>1,921,855</u>	<u>1,915,662</u>
Total liabilities and shareholders' equity	<u>2,961,813</u>	<u>2,952,366</u>	<u>2,242,148</u>	<u>2,239,247</u>

The accompanying notes are an integral part of the financial statements.

.....
Directors
.....

(Unaudited but reviewed)

Inter Pharma Public Company Limited and its subsidiaries**Statements of comprehensive income****For the three-month period ended 31 March 2024**

(Unit: Thousand Baht, except earnings per share expressed in Baht)

	Note	Consolidated financial statements		Separate financial statements	
		2024	2023 (Restated)	2024	2023
Profit or loss:					
Revenues					
Revenue		484,277	473,031	160,217	152,740
Other income		3,132	4,456	15,544	10,704
Total revenues		<u>487,409</u>	<u>477,487</u>	<u>175,761</u>	<u>163,444</u>
Expenses					
Cost of sales and services		301,876	285,304	102,190	77,023
Selling and distribution expenses		108,831	74,440	40,115	23,327
Administrative expenses		50,970	55,591	22,713	18,647
Total expenses		<u>461,677</u>	<u>415,335</u>	<u>165,018</u>	<u>118,997</u>
Operating profit		25,732	62,152	10,743	44,447
Share of loss from investments in joint venture	7	(225)	(527)		-
Finance cost		(5,241)	(6,776)	(2,803)	(4,361)
Profit before income tax expenses		20,266	54,849	7,940	40,086
Income tax expenses	14	(5,136)	(14,052)	(1,747)	(8,032)
Profit for the period		<u>15,130</u>	<u>40,797</u>	<u>6,193</u>	<u>32,054</u>
Other comprehensive income for the period		-	-	-	-
Total comprehensive income for the period		<u>15,130</u>	<u>40,797</u>	<u>6,193</u>	<u>32,054</u>
Profit (loss) attributable to:					
Equity holders of the Company		15,796	39,167	6,193	32,054
Non-controlling interests of the subsidiaries		(666)	1,630		
		<u>15,130</u>	<u>40,797</u>		
Total comprehensive income attributable to:					
Equity holders of the Company		15,796	39,167	6,193	32,054
Non-controlling interests of the subsidiaries		(666)	1,630		
		<u>15,130</u>	<u>40,797</u>		
Earnings per share					
	16				
Basic earnings per share (Baht)					
Profit attributable to equity holders of the Company		<u>0.0424</u>	<u>0.1051</u>	<u>0.0166</u>	<u>0.0860</u>
Weighted average number of ordinary shares (Thousand shares)					
		<u>372,521</u>	<u>372,521</u>	<u>372,521</u>	<u>372,521</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Inter Pharma Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity

For the three-month period ended 31 March 2024

(Unit: Thousand Baht)

Consolidated financial statements									
Equity attributable to owners of the Company									
			Surplus on	Surplus from	Retained earnings		Total equity	Equity attributable	Total
	Issued and	Share premium	share-based	business	Appropriated -	Unappropriated	attributable to	to non-controlling	shareholders'
	paid-up		payment	combination under	statutory reserve		owners of	interests of	equity
	share capital		transactions	common control			the Company	the subsidiaries	
Balance as at 31 December 2022									
- as previously reported	186,260	1,479,698	18,273	3,703	20,243	218,381	1,926,558	147,021	2,073,579
Effect of adjustment of the provisional amounts recognised from the busienss acquisition (Note 6)	-	-	-	-	-	(361)	(361)	43,233	42,872
Balance as at 31 December 2022 - as restated	186,260	1,479,698	18,273	3,703	20,243	218,020	1,926,197	190,254	2,116,451
Profit for the period (Restated)	-	-	-	-	-	39,167	39,167	1,630	40,797
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	39,167	39,167	1,630	40,797
Balance as at 31 March 2023 - as restated	186,260	1,479,698	18,273	3,703	20,243	257,187	1,965,364	191,884	2,157,248
Balance as at 1 January 2024	186,260	1,479,698	18,273	3,703	23,153	202,100	1,913,187	204,534	2,117,721
Profit (loss) for the period	-	-	-	-	-	15,796	15,796	(666)	15,130
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	15,796	15,796	(666)	15,130
Balance as at 31 March 2024	186,260	1,479,698	18,273	3,703	23,153	217,896	1,928,983	203,868	2,132,851

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Inter Pharma Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity (continued)

For the three-month period ended 31 March 2024

(Unit: Thousand Baht)

	Separate financial statements					
	Issued and paid-up share capital	Share premium	Surplus on share-based payment transactions	Retained earnings Appropriated - statutory reserve	Unappropriated	Total shareholders' equity
Balance as at 1 January 2023	186,260	1,479,698	18,273	20,243	217,482	1,921,956
Profit for the period	-	-	-	-	32,054	32,054
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	32,054	32,054
Balance as at 31 March 2023	<u>186,260</u>	<u>1,479,698</u>	<u>18,273</u>	<u>20,243</u>	<u>249,536</u>	<u>1,954,010</u>
Balance as at 1 January 2024	186,260	1,479,698	18,273	23,153	208,278	1,915,662
Profit for the period	-	-	-	-	6,193	6,193
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	6,193	6,193
Balance as at 31 March 2024	<u>186,260</u>	<u>1,479,698</u>	<u>18,273</u>	<u>23,153</u>	<u>214,471</u>	<u>1,921,855</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Inter Pharma Public Company Limited and its subsidiaries**Statements of cash flows****For the three-month period ended 31 March 2024**

(Unit: Thousand Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	<u>2024</u>	<u>2023</u> (Restated)	<u>2024</u>	<u>2023</u>
Cash flows from operating activities				
Profit before tax	20,266	54,849	7,940	40,086
Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities:				
Depreciation and amortisation	26,222	24,589	2,994	2,317
Impairment loss on financial assets (reversal)	3,147	(732)	-	-
Reduction of inventory to net realisable value	3,835	2,578	2,086	270
Reversal of provision of goods return	(159)	(370)	(148)	(373)
Loss from sales/write-off of property, plant and equipment and right-of-use assets	359	479	486	5
Net difference of right-of-use assets and lease liabilities arising from termination of contracts	-	(1,312)	-	-
Share of loss from investments in joint venture	225	527	-	-
Provision for long-term employee benefits	1,348	1,959	772	957
Unrealised loss (gain) on exchange	(158)	(22)	(143)	256
Finance income	(129)	(138)	(1,797)	(1,860)
Finance cost	5,241	6,776	2,803	4,361
Profit from operating activities before changes in operating assets and liabilities	60,197	89,183	14,993	46,019
Operating assets (increase) decrease				
Trade and other receivables	(6,016)	3,557	(24,115)	23,189
Advanced payments for purchase of goods	1,088	(2,562)	1,088	(2,671)
Inventories	(1,024)	(8,398)	(1,451)	(6,124)
Other current assets	3,216	57	104	648
Deposits	(2,055)	(2,017)	-	293
Other non-current assets	416	115	113	399
Operating liabilities increase (decrease)				
Trade and other payables	2,807	12,628	15,138	(8,367)
Other current liabilities	(167)	(259)	109	(1,235)
Other non-current liabilities	672	-	-	-
Cash flows from operating activities	59,134	92,304	5,979	52,151
Interest received	2	32	-	1
Cash paid for employee benefits	(436)	-	(200)	-
Cash paid for income tax	(1,215)	(1,017)	(289)	(162)
Net cash from operating activities	57,485	91,319	5,490	51,990

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

Inter Pharma Public Company Limited and its subsidiaries**Statements of cash flows (continued)****For the three-month period ended 31 March 2024**

(Unit: Thousand Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	<u>2024</u>	<u>2023</u> (Restated)	<u>2024</u>	<u>2023</u>
Cash flows from investing activities				
Cash paid for advance payment for business study	(11,029)	-	(11,029)	-
Long-term loans to subsidiaries	-	-	(1,000)	(55,000)
Cash received from repayment of long-term loans to subsidiaries	-	-	30,000	-
Cash received from repayment of long-term loans to employees	-	5	-	5
(Increase) decrease in other current financial assets	1	-	(3)	-
Purchase of property, plant and equipment	(32,064)	(23,834)	(16,668)	(1,507)
Purchase of intangible assets	(14,275)	-	(14,352)	-
Cash received from sale of property, plant and equipment	641	20	514	20
Interest received	127	101	1,773	1,866
Net cash used in investing activities	(56,599)	(23,708)	(10,765)	(54,616)
Cash flows from financing activities				
Cash received from short-term loans from bank	-	5,000	-	-
Cash paid to settle short-term loans from bank	-	(30,000)	-	-
Cash paid to settle long-term loans from bank	(14,298)	(18,106)	(11,550)	(15,450)
Cash received from long-term loans from related parties	-	6,000	-	-
Payment of principal portion of lease liabilities	(9,563)	(7,210)	(149)	(133)
Interest paid	(6,251)	(6,577)	(2,658)	(4,202)
Net cash used in financing activities	(30,112)	(50,893)	(14,357)	(19,785)
Net increase (decrease) in cash and cash equivalents	(29,226)	16,718	(19,632)	(22,411)
Cash and cash equivalents at beginning of the period	412,390	776,422	252,170	599,117
Effect of change in foreign exchange rate on cash at banks	149	13	124	(10)
Cash and cash equivalents at end of the period	383,313	793,153	232,662	576,696

Supplemental disclosures of cash flows information:

Non-cash related transactions

Increase (decrease) in other payable for purchases of property, plant and equipment and intangible assets	929	(1,611)	(9,375)	-
Acquisition of right-of-use assets under lease contracts	9,096	22,043	-	924
Transfer provision for long-term employee benefits to subsidiary	-	-	838	-

The accompanying notes are an integral part of the financial statements.

Inter Pharma Public Company Limited and its subsidiaries

Notes to interim financial statements

For the three-month period ended 31 March 2024

1. General information

1.1 Corporate information

Inter Pharma Public Company Limited (“the Company”) was incorporated as a limited company under Thai laws and registered the change of the Company’s status to be the public company limited under the Public Limited Companies Act on 15 May 2019 and registered with the Market for Alternative Investment (MAI) on 5 November 2019. The Company is principally engaged in the import, manufacture and distribute of drug, dietary supplement product for humans and animals by appoint a distributor company to handle the distribution.

1.2 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 “Interim Financial Reporting”, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements.

These interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language interim financial statements.

1.3 Basis of consolidation

These interim consolidated financial statements include the financial statements of Inter Pharma Public Company Limited and its subsidiaries and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2023 with no changes in shareholding structure of subsidiaries during the current period.

1.4 Accounting policies

The interim financial statements are prepared by using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 December 2023.

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2024, do not have any significant impact on the Group's financial statements.

2. Related party transactions

During the periods, the Group had significant business transactions with its individual and related parties. Such transactions arose in the ordinary course of business, and were concluded on commercial terms and based agreed upon between the Group and those related parties. There were no significant changes in the transfer pricing policy of transactions with related parties during the current period.

Summaries significant business transactions with related parties are as follows:

(Unit: Thousand Baht)

	For the three-month periods ended 31 March			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
<u>Transactions with subsidiaries</u>				
<i>(eliminated from the consolidated financial statements)</i>				
Sales of goods	-	-	30,058	7,259
Other income	-	-	12,706	7,312
Interest income	-	-	1,671	1,758
<u>Transactions with joint venture</u>				
Sales of goods	-	79	-	79
Other income	426	-	426	-
Purchase of goods	1,050	1,314	1,050	1,268
<u>Transactions with related parties</u>				
Sales of goods	1,528	1,762	-	-
Purchase of goods	9,569	10,524	-	-
Interest expenses	48	48	-	-

(Unaudited but reviewed)

The outstanding balances between the Company and those related parties as at 31 March 2024 and 31 December 2023 are as follows:

	Consolidated		(Unit: Thousand Baht)	
	financial statements		Separate	
	31 March	31 December	31 March	31 December
	2024	2023	2024	2023
		(Audited)		(Audited)
<u>Trade and other receivables</u>				
<u>- related parties</u>				
Subsidiary companies	-	-	106,596	101,875
Joint venture	477	1,619	477	1,619
Related companies (related by common shareholders and/or directors)	728	734	-	-
Total trade and other receivables - related parties	1,205	2,353	107,073	103,494
Less: Allowance for expected credit losses	(10)	(9)	-	-
Total trade and other receivables - related parties - net (Note 3)	1,195	2,344	107,073	103,494
<u>Long-term loans to related parties</u>				
<u>Subsidiary companies</u>				
Inter Wellness Co., Ltd.	-	-	2,000	1,000
Inter Vetta Co., Ltd.	-	-	7,000	7,000
Inter Petrina Co., Ltd.	-	-	7,200	7,200
Modern Pharma Co., Ltd.	-	-	96,000	126,000
Total long-term loans to related parties	-	-	112,200	141,200

As at 31 March 2024, the Company had long-term loans to related parties of Baht 112.2 million (31 December 2023: Baht 141.2 million), bearing interest at the rate of 5.0 percent per annum and due for repayment within 31 December 2025 to 31 December 2027 (31 December 2023: 5.0 percent per annum and due for repayment within 31 December 2025 to 31 December 2027).

During the three-month period ended 31 March 2024, movement of long-term loans to related parties are as follows:

	(Unit: Thousand Baht)	
	Consolidated	Separate
	financial	financial
	statements	statements
Balance as at 1 January 2024	-	141,200
Increase during the period	-	1,000
Decrease during the period	-	(30,000)
Balance as at 31 March 2024	-	112,200

(Unaudited but reviewed)

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2024	2023	2024	2023
		(Audited)		(Audited)
<u>Trade and other payables - related parties</u>				
Subsidiary companies	-	-	1,618	10,254
Joint venture	291	251	291	251
Related companies (related by common shareholders and/or directors)	2,067	3,364	-	-
Related person - directors	2,150	1,879	-	-
Total trade and other payables - related parties (Note 11)	4,508	5,494	1,909	10,505
<u>Long-term loans from related parties</u>				
Related company (related by common shareholders and/or directors)	4,800	4,800	-	-
Total long-term loans from related parties	4,800	4,800	-	-

As at 31 March 2024, the Group had long-term loans from related parties of Baht 4.8 million (31 December 2023: 4.8 million), bearing interest at the rate of 4 percent per annum and due for repayment after 31 March 2025 (31 December 2023: 4 percent per annum and due for repayment after 31 December 2024).

During the three-month period ended 31 March 2024, there is no movement of long-term loans from related party.

Directors and management's remuneration

During the three-month periods ended 31 March 2024 and 2023, the Group had employee benefit expenses of their directors and management as below.

(Unit: Thousand Baht)

	For the three-month periods ended 31 March			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Short-term employee benefits	12,230	10,758	5,620	4,987
Post-employment benefits	366	479	318	461
Total	12,596	11,237	5,938	5,448

3. Trade and other receivables

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March 2024	31 December 2023	31 March 2024	31 December 2023
	(Audited)		(Audited)	
<u>Trade accounts receivable - related parties</u>				
Aged on the basis of due dates				
Not yet due	681	726	27,612	36,872
Overdue not over 30 days	7	6	4,655	5,512
Overdue 31 - 60 days	5	-	25,760	12,093
Overdue 61 - 90 days	5	2	5,445	4,896
Overdue 91 - 180 days	30	-	-	3,530
Total trade accounts receivable - related parties	728	734	63,472	62,903
Less: Allowance for expected credit losses	(10)	(9)	-	-
Total trade accounts receivable - related parties - net (Note 2)	718	725	63,472	62,903

(Unaudited but reviewed)

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2024	2023	2024	2023
		(Audited)		(Audited)
<u>Trade accounts receivable sold through the distributor</u>				
Aged on the basis of due dates				
Not yet due	150,317	173,184	59,852	66,379
Overdue not over 30 days	30,889	26,415	-	-
Overdue 31 - 60 days	6,754	7,294	-	-
Overdue 61 - 90 days	2,813	4,387	-	-
Overdue 91 - 180 days	4,798	1,793	-	-
Overdue 181 - 365 days	2,220	2,107	-	-
Overdue more than 365 days	4,431	4,108	167	167
Total trade accounts receivable sold through the distributor	202,222	219,288	60,019	66,546
Less: Allowance for expected credit losses	(8,718)	(7,555)	(167)	(167)
Total trade accounts receivable sold through the distributor - net	193,504	211,733	59,852	66,379
<u>Trade accounts receivable - unrelated parties</u>				
Aged on the basis of due dates				
Not yet due	100,373	84,516	66,258	36,972
Overdue not over 30 days	27,579	18,270	882	581
Overdue 31 - 60 days	8,843	7,936	863	152
Overdue 61 - 90 days	4,866	3,459	-	725
Overdue 91 - 180 days	5,193	8,930	-	2,836
Overdue 181 - 365 days	4,971	5,166	-	-
Overdue more than 365 days	14,920	13,470	4,357	4,357
Total trade accounts receivable - unrelated parties	166,745	141,747	72,360	45,623
Less: Allowance for expected credit losses	(18,872)	(16,889)	(4,357)	(4,357)
Total trade accounts receivable - unrelated parties - net	147,873	124,858	68,003	41,266
Total trade accounts receivable - net	342,095	337,316	191,327	170,548
<u>Other receivables</u>				
Other receivables - related parties (Note 2)	477	1,619	43,601	40,591
Other receivables - unrelated parties	85,357	86,125	42,687	42,337
Total other receivables	85,834	87,744	86,288	82,928
Total trade and other receivables - net	427,929	425,060	277,615	253,476

Trade accounts receivable sold through the distributor is presented with the balance before deducting service discount for distribution that the Group has to pay to the distributor when the goods are sold to retail customer via the distributor.

The aging of the end customer receivable sold through distributor has the following criteria:

- (1) In case the distributor is responsible for the risk in terms of the credit term of end customer receivable, the aging is held by the credit term granted by the Group to the distributor as specified in the distributor agreement by starting the aging count from the month-end that the Group sells to its end customer through the distributor.
- (2) In case the Group is responsible for the risk in terms of the credit term of end customer receivable, the aging is held by the credit term granted by the distributor to the end customer receivable as specified in the distributor agreement. But, the distributor will be responsible only for debt collection by starting the aging count from the day that the Group sells to its end customer through the distributor.

4. Reduction of inventories to net realisable value

Movements in reduction of inventories to net realisable value account during the three-month period ended 31 March 2024 are summarised below.

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
	<u> </u>	<u> </u>
Balance as at 1 January 2024	7,081	2,871
Add: Reduction of inventory value during the period	4,186	2,093
Less: Reversal of reduction of inventory value during the period	<u>(351)</u>	<u>(7)</u>
Balance as at 31 March 2024	<u>10,916</u>	<u>4,957</u>

5. Advance payment for business study

During the first quarter of 2024, the Company made payment of Baht 11.03 million as deposit for business study.

(Unaudited but reviewed)

(Unit: Thousand Baht)

For the three-month
period ended

31 March 2023

Statement of comprehensive income

Increase in cost of sale and services	1,102
Increase in administrative expenses	690
Decrease in profit for the period	(1,792)
Decrease in total comprehensive income for the period	(1,792)
Profit attributable to:	
Decrease in equity holders of the Company	(896)
Total comprehensive income attributable to:	
Decrease in equity holders of the Company	(896)
Earnings per share (Baht)	
Decrease in basic earnings per shares	(0.0024)

7. Investments in joint venture

		(Unit: Thousand Baht)							
		Consolidated				Separate			
		financial statements				financial statements			
		Carrying amount based				Carrying amount			
		on equity method				based on cost method			
		31		31		31		31	
		March		December		March		December	
		2024		2023		2024		2023	
Company name	Nature of business	March 2024	December 2023	March 2024	December 2023	March 2024	December 2023	March 2024	December 2023
Interpharma-ZEAvita Co., Ltd.	Develop and distribute supplementary health food products	20,000	20,000	51	51	6,854	7,079	10,200	10,200
Total						6,854	7,079	10,200	10,200

(Unaudited but reviewed)

During the three-month periods ended 31 March 2024 and 2023, the Company recognised share of comprehensive income from investment in joint venture in the consolidated financial statements and recognised dividend income in the separate financial statements as follows:

	Consolidated		(Unit: Thousand Baht)	
	financial statements		Separate financial statements	
Share of loss from investment in joint venture for the three-month periods ended 31 March			Dividend received during the three-month periods ended 31 March	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Interpharma-ZEAvita Co., Ltd.	(225)	(527)	-	-

8. Property, plant and equipment

Movements of the property, plant and equipment account during the three-month period ended 31 March 2024 are summarised below.

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
Net book value as at 1 January 2024	822,375	211,616
Acquisition during the period - cost	31,994	14,543
Disposals during the period - net book value as at disposal date	(1,000)	(1,000)
Depreciation for the period	(11,418)	(2,331)
Net book value as at 31 March 2024	<u>841,951</u>	<u>222,828</u>

9. Right-of-use assets

Movements of the right-of-use assets account during the three-month period ended 31 March 2024 are summarised below.

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
Net book value as at 1 January 2024	106,897	2,884
Increase during the period	9,239	-
Depreciation for the period	(11,165)	(169)
Net book value as at 31 March 2024	<u>104,971</u>	<u>2,715</u>

10. Short-term loans from banks

	(Unit: Thousand Baht)					
	Interest rate		Consolidated		Separate	
	(percent per annum)		financial statements		financial statements	
	31 March	31 December	31 March	31 December	31 March	31 December
2024	2023	2024	2023	2024	2023	
			(Audited)		(Audited)	
Promissory notes	MLR-1.0, 3.55	MLR-1.0, MLR-1.5	40,000	40,000	-	-
Total			40,000	40,000	-	-

During the three-month period ended 31 March 2024, there is no movement of short-term loans from banks.

The Group

The Group had short-term loans from bank which were in form of promissory notes. The loans are secured by mortgage of land with structures thereon and guaranteed of trade receivables of the subsidiaries.

The Company

On 30 May 2023, the Company has entered into a credit facilities agreement with a bank, obtaining a loan facility of Baht 50 million to be used as working capital and business expansion. The term of the agreement is 20 years and secured by bank deposits of Baht 50 million and its interest.

(Unaudited but reviewed)

11. Trade and other payables

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2024	2023	2024	2023
		(Audited)		(Audited)
Trade accounts payable - related parties (Note 2)	2,310	3,567	291	251
Trade accounts payable - unrelated parties	196,715	196,955	39,142	30,453
Other payables - related parties (Note 2)	-	-	1,618	10,254
Other payables - unrelated parties	26,733	20,632	16,414	12,346
Notes payable	126	240	29	121
Accrued expenses - related parties (Note 2)	2,198	1,927	-	-
Accrued expenses - unrelated parties	35,517	42,350	5,199	4,658
Other payable - distributor	29,106	27,664	4,657	4,935
Others	31,230	28,175	3,579	1,329
Total trade and other payables	323,935	321,510	70,929	64,347

12. Long-term loans from banks

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March	31 December	31 March	31 December
	2024	2023	2024	2023
		(Audited)		(Audited)
Long-term loans from banks	241,213	255,511	219,721	231,271
Less: Deferred finance cost	(387)	(427)	(387)	(427)
Long-term loans from banks - net	240,826	255,084	219,334	230,844
Less: Portion due within one year	(53,360)	(54,427)	(46,060)	(46,052)
Long-term loans from banks - net of current portion	187,466	200,657	173,274	184,792

During the three-month period ended 31 March 2024, movements in long-term loans from bank are summarised below.

	(Unit: Thousand Baht)	
	Consolidated financial statements	Separate financial statements
Balance as at 1 January 2024	255,084	230,844
Add: Amortisation of finance cost	40	40
Less: Repayment during the period	(14,298)	(11,550)
Balance as at 31 March 2024	<u>240,826</u>	<u>219,334</u>

The Company

1. On 25 August 2021, the Company has additionally entered into a long-term loan agreement with a bank, obtaining a loan facility of Baht 120 million to be used as working capital and business expansion. The agreement term of such loans is 7 years and are repayable in 84 monthly installments of Baht 1.45 million. The loans carry interest as follows:

- The 1st - 24th month has interest rate at the rate of MLR - 1.50 % per annum.
- The 25th month onwards has interest at the rate of to MLR - 1.25 % per annum.

On 23 November 2023, bank has revised interest rate to be MLR-2.5% per annum which has been effective from 28 October 2023 onwards.

2. On 28 March 2022, the Company has additionally entered into a long-term loan agreement with such bank, obtaining a loan facility of Baht 200 million to be used as working capital and business expansion. The agreement term of such loans is 7 years and are repayable in 84 monthly installments of Baht 2.4 million. The loans carry interest as follows:

- The 1st - 24th month has interest rate at the rate of MLR - 1.50 % per annum.
- The 25th month onwards has interest at the rate of to MLR - 1.25 % per annum.

On 23 November 2023, bank has revised interest rate to be MLR-2.5% per annum which has been effective from 8 October 2023 onwards.

Modern Pharma Co., Ltd.

On 9 July 2021, Modern Pharma Co., Ltd. (the subsidiary) has entered into long-term loan agreements with a bank, obtaining loan facilities of Baht 19 million to be used as business expansion. The agreement term of such loans is 7 years and are repayable in 84 monthly installments of Baht 0.23 million. The loans carry interest as follows:

- The 1st - 24th month has interest rate at the rate of MLR - 1.50 % per annum.
- The 25th month onwards has interest at the rate of to MLR - 1.25 % per annum.

On 23 November 2023, bank has revised interest rate to be MLR-2.5% per annum which has been effective from 22 October 2023 onwards.

Nakhon Patana Co., Ltd.

1. On 19 May 2016, Nakhon Patana Co., Ltd. (the subsidiary) has entered into a long-term loan agreement with a bank, obtaining a loan facility of Baht 50 million to be used as working capital and business expansion. The agreement term of such loans is 5 years and 7 months and are repayable in 67 monthly installments of Baht 0.39 million. The loans carry interest as follows:

- The 1st - 36th month has interest rate at the rate of MLR - 0.50 % per annum.
- The 37th - 60th month has interest rate at the rate of MLR - 0.25% per annum.
- The 61st month onwards has interest at the rate of MLR per annum.

2. On 9 September 2021, the subsidiary has additionally entered into a long-term loan agreement with such bank, obtaining a loan facility of Baht 18 million to be used as working capital and business expansion. The agreement term of such loans is 4 years and 2 months and are repayable in 50 monthly installments of Baht 0.36 million. The loans carry interest at the rate of MLR - 0.25% per annum.

As at 31 March 2024, the Group had outstanding balance of long-term loans of Baht 240.83 million (31 December 2023: Baht 255.08 million) and the Company had outstanding balance of such long-term loans of Baht 219.33 million (31 December 2023: Baht 230.84 million).

As at 31 March 2024 and 31 December 2023, the Group had no outstanding long-term loan credit facilities.

The loans are secured by mortgage of land and structures and machineries thereon, owned by the Group.

The loan agreements contain covenants with which the Group has to comply, pertaining to matters such as maintaining of debt-to-equity ratio, maintaining of percentage of shares held by the major shareholder and main management of the Company.

(Unaudited but reviewed)

13. Lease liabilities

	(Unit: Thousand Baht)			
	Consolidated		Separate	
	financial statements		financial statements	
	31 March 2024	31 December 2023	31 March 2024	31 December 2023
			(Audited)	
Lease liabilities	104,351	105,114	3,214	3,407
Less: Deferred interest expenses	(11,095)	(11,391)	(404)	(448)
Total	93,256	93,723	2,810	2,959
Less: Portion due within one year	(35,703)	(38,892)	(619)	(610)
Lease liabilities - net of current portion	57,553	54,831	2,191	2,349

During the three-month period ended 31 March 2024, movements in lease liabilities are summarised below.

	(Unit: Thousand Baht)	
	Consolidated	Separate
	financial statements	financial statements
Balance as at 1 January 2024	93,723	2,959
Add: Increase during the period	9,096	-
Less: Payments during the period	(9,563)	(149)
Balance as at 31 March 2024	93,256	2,810

14. Income tax

Interim corporate income tax was calculated on profit before income tax for the period, using the estimated effective tax rate for the year.

Income tax expenses for the three-month periods ended 31 March 2024 and 2023 are made up as follows:

(Unit: Thousand Baht)

	For the three-month periods ended 31 March			
	Consolidated		Separate	
	financial statements		financial statements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Current income tax:				
Interim corporate income tax charge	5,628	10,325	2,274	8,328
Deferred tax:				
Relating to origination and reversal of temporary differences	(492)	3,727	(527)	(296)
Income tax expenses reported in the profit or loss	<u>5,136</u>	<u>14,052</u>	<u>1,747</u>	<u>8,032</u>

15. Warrants

On 27 April 2023, the Annual General Meeting of shareholders of the Company passed the resolutions approving the issuance of 2nd warrants (“IP-W2 WARRANT”). Details of the warrants are summarised below.

Number of warrants issued	: 93,129,691 warrants
Offering price	: Baht 0 per unit
Offering method	: Offer to the existing shareholders in proportionate to their respective shareholding at the ratio of 4 ordinary share to 1 unit of IP-W2
Exercise ratio and price	: 1 warrant per 1 newly issued ordinary share at a price of Baht 20 per share
Date of issuance	: 21 June 2023
Term of the warrant	: 2 years from the issuance date of warrants
Expiry date	: 20 June 2025
Exercise dates	: On the last business day of December whereby the first and last exercise dates are 29 December 2023 and 20 June 2025

Subsequently on 26 April 2024, the Annual General Meeting of the Company's shareholders passed the resolutions approving the right adjustment of warrant from 1 warrant per 1 newly issued ordinary share at a price of Baht 20 per share to 1 warrant per 1.626 newly issued ordinary share at a price of Baht 12.308 per share.

Movements of warrant during the period are summarised below.

	Number of units (units)
Warrants issued as at 1 January 2024	<u>93,129,691</u>
Warrants issued as at 31 March 2024	<u><u>93,129,691</u></u>

16. Earnings per share

Basic earnings per share is calculated by dividing profit for the period (excluding other comprehensive income) by the weighted average number of ordinary shares issued during the period, and adjusted the number of ordinary shares with the proportionate change in the number of ordinary shares as a result of the exercise of warrants.

Diluted earnings per share is calculated by dividing profit for the period (excluding other comprehensive income) by the sum of the weighted average number of ordinary shares in issue during the period plus the weighted average number of ordinary shares which would need to be issued to convert all dilutive potential ordinary shares into ordinary shares. The calculation assumes that the conversion took place either at the beginning of the year or on the date the potential ordinary shares were issued.

As at 31 March 2024 and 2023, the warrants are excluded from the potential ordinary shares since their exercise price is in excess of the fair value of the ordinary shares.

17. Segment information

The Group is organised into business units based on their products and services. During the current period, the Group has not changed the organisation of its reportable segments from the last annual financial statements.

(Unaudited but reviewed)

The following table presents revenue and profit information regarding the Group's operating segments for the three-month period ended 31 March 2024 and 2023:

(Unit: Thousand Baht)

	Consolidated financial statements							
	For the three-month periods ended 31 March							
	Human healthcare		Animal healthcare		Hospital		Total	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Revenue	354,245	336,129	80,941	83,440	49,091	53,462	484,277	473,031
Cost of sales and services	<u>(204,476)</u>	<u>(190,141)</u>	<u>(57,203)</u>	<u>(53,646)</u>	<u>(40,197)</u>	<u>(41,517)</u>	<u>(301,876)</u>	<u>(285,304)</u>
Gross profit	<u>149,769</u>	<u>145,988</u>	<u>23,738</u>	<u>29,794</u>	<u>8,894</u>	<u>11,945</u>	182,401	187,727
Other income							3,132	4,456
Selling and distribution expenses							(108,831)	(74,440)
Administrative expenses							(50,970)	(55,591)
Share of loss from investments								
in joint venture							(225)	(527)
Finance cost							(5,241)	(6,776)
Income tax expenses							(5,136)	(14,052)
Profit for the period							<u>15,130</u>	<u>40,797</u>

Major customers

The Group has no retail customer through distributor with revenue of 10 percent or more of the Group's revenues.

18. Commitments and contingent liabilities

18.1 Commitments and bank guarantees

(Unit: Million Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	31 March 2024	31 December 2023	31 March 2024	31 December 2023
		(Audited)		(Audited)
Commitment on purchase of goods and service	134.0	131.4	82.7	75.1
Commitment on service agreements	29.8	28.7	7.6	3.2
Capital commitments	97.5	80.5	36.4	36.9
Bank guarantees	6.7	6.7	-	-

18.2 Commitment on distribution agreements

As at 31 March 2024, the Group has commitment under the distributor agreements with a local company. Such distributor agreements are effective from 1 September 2018 ending 31 August 2023 and extended until end at 31 August 2026. The Group has committed to pay service fees for distribution to such company at a percentage of sale as specified in the agreements.

19. Litigation

On 26 February 2022, the Company and its subsidiary was filed by a company on the transfer of rights on debt collection. Currently, the case is under hearing of the Court of Appeal. The Company and its subsidiary considered that there will be no any additional liabilities to be recorded.

20. Events after the reporting period

On 26 April 2024, the Annual General Meeting of the Company's shareholders approved the following:

1. Payment of a dividend for the operating results of the year 2023 of Baht 0.3473 per share, totaling Baht 129.38 million. The schedule for payment is as follows:
 - (1) Pay dividends in ordinary shares of the Company at 8 former shares to 5 dividend share in total dividend shares of 232.83 million shares at the par value of Baht 0.50 per share, totaling Baht 116.41 million or dividend payout ratio at Baht 0.3125 per share. If any shareholder has any fraction of the existing shares after dividend shares appropriation, the dividends shall be paid in cash instead of dividend shares at Baht 0.3125 per share.
 - (2) Pay dividends in cash at Baht 0.0348 per share, totaling Baht 12.96 million (to accommodate for withholding tax of assessable income pursuant to the applicable law).
2. Approved the reduction in its registered share capital from Baht 243,363,711.50 (486,727,423 ordinary shares of Baht 0.50 per share) to Baht 232,825,107.50 (465,650,215 ordinary shares of Baht 0.50 per share) by cancelling the 21,077,208 ordinary shares with a par value of Baht 0.50 each which reserved for the exercise of the warrants to purchase ordinary shares of the IP-W1 and the remaining shares from the reserve for the exercise of the warrants to purchase ordinary shares of IP-W2.
3. Approved the increase in its registered share capital from Baht 232,825,107.50 (465,650,215 ordinary shares of Baht 0.50 per share) to Baht 378,387,365 (756,774,730 ordinary shares of Baht 0.50 per share) through the issuance of 291,124,515 additional ordinary shares of Baht 0.50 each share to reserve for the payment of dividend shares and the right adjustment of the warrants to purchase ordinary shares of IP-W2.

21. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 13 May 2024.